English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 19 December 2019, 08:40 HKT/SGT
Viva Biotech Was Included as a Constituent Stock of the Hang Seng Hong Kong-Listed Biotech Index

HONG KONG, Dec 19, 2019 - (ACN Newswire) - Viva Biotech Holdings ("Viva Biotech" or the "Company"; stock code: 1873.HK), the world leading operator of a structure-based drug discovery (SBDD) platform, is included as a constituent stock of the Hang Seng Hong Kong-Listed Biotech Index.

On 16 Dec 2019, Hang Seng Indexes Company Limited ("Hang Seng Indexes") launched the Hang Seng Hong Kong-Listed Biotech Index, which reflects the overall performance of biotech companies that are listed in Hong Kong. Universe of the selection includes all securities listed on the Main Board of the Stock Exchange of Hong Kong (including companies listed via Chapter 18A of the Listing Rules) and classified as 'Biotechnology', 'Pharmaceuticals', or 'Medical Devices' under the Hang Seng Industry Classification System. The selection criteria are securities ranking in the top 95% of the Universe in terms of 12-month-end average market value with 3-month average daily turnover of at least HKD 5 million.

The launching of the four new indexes, including the Hang Seng Hong Kong-Listed Biotech Index, demonstrates the wide acceptance of biotechnology industry in Hong Kong capital market. The inclusion is considered as the recognition of overall performance of Viva Biotech since its listing in May 2019. It is believed that it will further improve the company reputation among international capital markets.

About Viva Biotech Holdings
Viva Biotech's mission is to become a cradle for innovative biotechnology companies around the world. Viva Biotech has developed a scalable business model combing the conventional cash-for-service (CFS) model and its unique equity-for-service (EFS) model. Under the CFS model, the Group provides structure-based drug discovery services to its biotechnology and pharmaceutical customers worldwide for their pre-clinical stage innovative drug development, covering the full spectrum of the customers' needs for early stage drug discovery, including target protein expression and structure research, hit screening, lead optimization and drug candidate determination. Viva Biotech also provides drug discovery and incubation services to biotechnology start-up companies with high potential under its EFS model. As of June 30, 2019, Viva Biotech had provided drug discovery services to 388 biotechnology and pharmaceutical customers worldwide, worked on over 1,000 independent drug targets, delivered over 11,000 independent protein structures, and incubated a total of 37 early stage R&D projects.

Topic: Press release summary Sectors: Daily Finance, Daily News, BioTech
From the Asia Corporate News Network

Copyright © 2022 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.


Latest Press Releases
Wintermar Offshore (WINS:JK) Unveils Growth Strategy  
June 24, 2022 19:00 HKT/SGT
Toyota and Suzuki to Deepen Collaboration in the Fields of Development and Production in India  
Friday, June 24, 2022 6:16:00 PM
Murata and Mitsubishi Agree on a Cooperative Framework for Working Toward a Carbon-Neutral Society  
Friday, June 24, 2022 5:22:00 PM
32nd annual Hong Kong Book Fair returns on 20 July  
June 24, 2022 17:00 HKT/SGT
RHT Rajan Menon Foundation's GAIL Sustainability Forum shines spotlight on the road to COP27  
June 24, 2022 16:30 HKT/SGT
CleverTap Recognized by Great Place to Work Among India's Great Mid-size Workplaces  
June 24, 2022 15:00 HKT/SGT
CleverTap Recognized by Great Place to Work Among India's Great Mid-size Workplaces  
June 24, 2022 15:00 HKT/SGT
Spritzer wins Platinum Award in Reader's Digest Trusted Brands 2022  
June 24, 2022 11:00 HKT/SGT
Eisai Signs the Public-Private Partnership "Kigali Declaration" for Eliminating Neglected Tropical Diseases  
Friday, June 24, 2022 10:55:00 AM
Honda Joins Sustainable Aviation Fuel Review Panel   
Friday, June 24, 2022 9:42:00 AM
More Press release >>
More events >>
Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575